<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826018</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-HBV-001</org_study_id>
    <nct_id>NCT02826018</nct_id>
  </id_info>
  <brief_title>A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV)
      infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with
      HBV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has 3 parts. Part A is a single ascending dose (SAD) study in healthy volunteers.
      Part B is a single ascending dose study (SAD) in patients with HBV infection. Part C is a
      multiple ascending dose study (MAD) in patients with HBV infection.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing adverse events</measure>
    <time_frame>Part A (SAD phase): through Day 29; Part B (SAD phase): through Day 85; Part C (MAD phase): through Day 176</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-HBV</measure>
    <time_frame>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-HBV</measure>
    <time_frame>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</time_frame>
    <description>Elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-HBV</measure>
    <time_frame>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantitative hepatitis B surface antigen (HBsAg) levels</measure>
    <time_frame>Part B (SAD phase): baseline through Day 85; Part C (MAD phase): baseline through Day 176</time_frame>
    <description>Change in HBsAg levels from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Chronic Hepatitis B</condition>
  <condition>Hepatitis B, Chronic</condition>
  <condition>Hepatitis B Infection</condition>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>ALN-HBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-HBV</intervention_name>
    <description>Ascending doses of ALN-HBV by subcutaneous (sc) injection</description>
    <arm_group_label>ALN-HBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  18 to 65 years inclusive

          -  Women of child-bearing potential must have a negative pregnancy test, cannot be breast
             feeding, and must be willing to use a highly effective method of contraception

          -  Agrees not to donate blood during the duration of the study

          -  Willing to comply with the study requirements and to provide written informed consent

        Additional inclusion criteria for patients with HBV infection:

          -  Body mass index (BMI) â‰¥18.0 kg/m2

          -  Must be on a stable regimen of entecavir or tenofovir

        Exclusion Criteria:

        All subjects:

          -  Any uncontrolled or serious disease, or any medical or surgical condition, that may
             either interfere with participation in the clinical study, and/or put the subject at
             significant risk

          -  Subjects with a history of serious mental illness

          -  Active infection with human immunodeficiency virus (HIV) infection, hepatitis A virus
             (HAV), or hepatitis C virus (HCV) infection and/or a history of delta virus hepatitis

          -  Known hypersensitivity or contraindication to any medication or history of allergic
             reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc)

        Additional exclusion criteria for healthy volunteers:

          -  Evidence of liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Huang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Hepatitis B, Chronic</keyword>
  <keyword>Hepatitis B Infection</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

